Reviva Pharmaceuticals Holdings, Inc. develops therapies for central nervous system, inflammatory and cardiometabolic diseases as a late-stage biopharmaceutical company. News about RVPH centers on brilaroxazine (RP5063), a clinical-stage program for schizophrenia and other neuropsychiatric indications, as well as RP1208, with both drug candidates described as new chemical entities discovered in-house.
Recurring updates include clinical and regulatory communications, intellectual-property strategy, peer-reviewed data publications, corporate presentations, annual and interim financial results, and equity or warrant financings used to support research and development and working capital.
Reviva Pharmaceuticals (NASDAQ: RVPH) reported its first-quarter 2024 financial results and provided significant business updates. Key highlights include gaining FDA alignment on brilaroxazine's clinical trials for its NDA submission in schizophrenia, with the registrational RECOVER-2 trial set to begin in Q2 2024 and topline data expected Q3 2025. An open-label extension trial's topline data is anticipated in Q4 2024.
Financially, Reviva faced a net loss of $7.4 million for Q1 2024, compared to a $6.9 million loss in Q1 2023. The company's cash reserves dropped from $23.4 million at the end of 2023 to $12.0 million as of March 31, 2024. Upcoming catalysts include potential Phase 2a studies for bipolar disorder, major depressive disorder, and ADHD, and an IND submission for a liposomal-gel formulation of brilaroxazine in psoriasis in 2025.
Reviva Pharmaceuticals Holdings, Inc. will present new preclinical efficacy data on brilaroxazine in idiopathic pulmonary fibrosis at the 2024 ATS International Conference. The data will be presented by the CEO, Laxminarayan Bhat, in a late-breaking poster presentation. The presentation will focus on the effectiveness of brilaroxazine on functional and underlying pathological inflammation and fibrosis parameters in an animal model. This event will take place on May 21, 2024, in San Diego, CA.
Reviva Pharmaceuticals Holdings, Inc. will present new non-clinical pharmacology data on brilaroxazine at the ASPET 2024 Annual Meeting. The data will focus on drug transporter interaction and absorption, metabolism, and excretion in rats. The presentations will be held on May 19, 2024, by Founder and CEO Laxminarayan Bhat.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.